Paper EBITDA PLN 49m, above ABGSCe PLN 47m Group EBITDA beat driven mainly by Paper Outlook remains ...
Redeye provides its initial take on Mentice’s Q3 2024 report, which came in broadly below our estima...
Redeye considers Arise’s Q3 2024 report to be in line with our estimates, adjusted for the extra rev...
EBITDA +6% vs ABGSC and EBIT turned positive in Q3 We expect consensus to lift 2024 EBITDA by 10-15%...
Redeye shares its initial comments on Modelon’s Q3 2024 figures, which were in line with our ARR exp...
Sales SEK 344m -9% vs. ABGSCe 377m EBIT adj. for FX and cyberattack ~SEK -3m vs.
Q3 adj. EBIT of SEK 32m, +1% vs. ABGSC AUM flat q-o-q when adjusting for FX headwinds Q3 in line wit...
Redeye comments on the rights issue of SEK170m announced yesterday.
Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the c...
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits on...
Sales down 14% y-o-y as restaurant market headwinds intensify GC&MP strength improves mix, cost cont...
Redeye gives a brief comment on today’s news regarding Tesofensine, indicating that Tesofensine has ...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Administer's net sales declined by 3.9% y/y, reflecting the challenging market conditions that have ...
STENOCARE published on November 5th the company’s Q3-report for 2024.
